antihemophilic factor , AHF (Abkürzung)

Your pharmacist can provide more information about human antihemophilic factor.

Your body may develop antibodies to antihemophilic factor, making it less effective.

Human antihemophilic factor is usually given every 8 to 24 hours for 1 to 4 days, depending on the reason you are using the medication.

There may be other drugs not listed that can affect human antihemophilic factor.

Human antihemophilic factor is sometimes used only as needed, so you may not be on a dosing schedule.

Human antihemophilic factor is not for use in people with von Willebrand disease.

Human antihemophilic factor may also be used for other purposes not listed in this medication guide.

Human antihemophilic factor is given as an injection through a needle placed into a vein.

Do not use this medication if you have ever had a severe allergic reaction to antihemophilic factor in the past.

An overdose of human antihemophilic factor is not expected to produce life-threatening symptoms.

Follow your doctor's instructions about any restrictions on food, beverages, or activity while you are using human antihemophilic factor.

Human antihemophilic factor will not treat von Willebrand disease.

Human antihemophilic factor must be mixed with a liquid (diluent) before injecting it.

Your doctor may want you to receive a hepatitis vaccination before you start using human antihemophilic factor.

Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.

It is not known whether human antihemophilic factor passes into breast milk or if it could harm a nursing baby.

His team developed a concentrate of the antihemophilic factor, AHF, that provided an effective treatment.

Human antihemophilic factor is made from human plasma (part of the blood) and may contain viruses and other infectious agents that can cause disease.

This product contains a man-made form of factor VIII, also called antihemophilic factor.

A lack of antihemophilic factor VIII is the cause of hemophilia A.

Before using human antihemophilic factor, your specific blood clotting disorder must be diagnosed as factor VIII deficiency.

Brinkhous made the seminal discovery of antihemophilic factor (Factor VIII) and showed that it was lacking in hemophiliac patients.

In medicine genetic engineering has been used to mass-produce insulin, human growth hormones, follistim (for treating infertility), human albumin, monoclonal antibodies, antihemophilic factors, vaccines and many other drugs.

Moroctocog alfa is a glycoprotein (trade name ReFacto) and a recombinant Antihemophilic Factor genetically engineered from Chinese hamster ovary (CHO) cell line.

Human antihemophilic factor is used to treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia.